First Bank & Trust Has $202,000 Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

First Bank & Trust grew its position in Agilent Technologies, Inc. (NYSE:A) by 11.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,502 shares of the medical research company’s stock after purchasing an additional 150 shares during the period. First Bank & Trust’s holdings in Agilent Technologies were worth $202,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. McAdam LLC boosted its stake in shares of Agilent Technologies by 3.1% in the 3rd quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock valued at $376,000 after purchasing an additional 77 shares in the last quarter. Brown Brothers Harriman & Co. boosted its stake in shares of Agilent Technologies by 13.5% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 77 shares in the last quarter. Rovin Capital UT ADV lifted its position in Agilent Technologies by 1.6% during the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock worth $750,000 after buying an additional 81 shares in the last quarter. Integrated Advisors Network LLC lifted its position in Agilent Technologies by 2.5% during the 3rd quarter. Integrated Advisors Network LLC now owns 3,582 shares of the medical research company’s stock worth $532,000 after buying an additional 86 shares in the last quarter. Finally, Ascent Group LLC lifted its position in Agilent Technologies by 4.1% during the 3rd quarter. Ascent Group LLC now owns 2,209 shares of the medical research company’s stock worth $328,000 after buying an additional 87 shares in the last quarter.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the transaction, the chief executive officer now owns 39,652 shares of the company’s stock, valued at $5,947,800. This represents a 4.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Agilent Technologies Stock Performance

Shares of A stock opened at $136.74 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. The stock has a market cap of $39.01 billion, a PE ratio of 30.94, a price-to-earnings-growth ratio of 3.66 and a beta of 1.07. The stock has a 50-day moving average of $141.04 and a 200-day moving average of $139.28. Agilent Technologies, Inc. has a one year low of $124.16 and a one year high of $155.35.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 25th. The medical research company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. Agilent Technologies’s revenue was up .8% on a year-over-year basis. During the same period in the prior year, the business posted $1.38 EPS. As a group, sell-side analysts expect that Agilent Technologies, Inc. will post 5.56 earnings per share for the current year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.73%. Agilent Technologies’s payout ratio is 22.40%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on A shares. Wells Fargo & Company reduced their price target on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a research report on Monday, December 9th. JPMorgan Chase & Co. reduced their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 26th. Sanford C. Bernstein reduced their price target on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research report on Tuesday, November 26th. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Finally, Barclays upgraded shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and upped their price target for the stock from $135.00 to $145.00 in a research report on Monday, February 10th. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $144.38.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.